Helicobacter pylori infection
Conditions
Interventions
Experimental group A (dual therapy group):Vonoprazan + Doxycycline
Experimental group B (triple therapy group):Vonoprazan + Doxycycline + Bismuth Potassium Citrate
Control group (quadruple therapy group):Vonoprazan + Doxycycline + Bismuth Potassium Citrate + Metronidazole
Sponsors
The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years, regardless of gender; 2. Has a history of penicillin allergy or a positive penicillin skin test; 3. No use of antibiotics, bismuth agents, PPIs, or P-CABs within the past four weeks; 4. Positive 13C-urea breath test or gastroscopy-confirmed Helicobacter pylori infection; 5. Naive patients who agree to undergo H. pylori eradication therapy and are willing to cooperate with follow-up surveys on eradication efficacy.
Exclusion criteria
Exclusion criteria: 1. Individuals with severe impairment of cardiac, hepatic, or renal function; 2. Pregnant or lactating women; 3. History of previous *Helicobacter pylori* eradication therapy, upper gastrointestinal surgery, gastric malignancy, hepatic or renal impairment, pyloric stenosis, or pregnancy; 4. Participation in any other drug clinical trial within the 3 months prior to taking the study medication; 5. Concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) or a history of alcohol abuse; 6. Known allergy to any of the drugs used in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;Compliance; | — |
Countries
China
Contacts
Public ContactXiaoyong Wang
The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University
Outcome results
None listed